메뉴 건너뛰기




Volumn 14, Issue 1, 2014, Pages 103-114

Immunotherapy for recurrent ovarian cancer: A further piece of the puzzle or a striking strategy?

Author keywords

Antibody; Cancer vaccines; Cell transfer; Immune system; Immunotherapy; Ovarian cancer; Recurrence; Treatment strategies

Indexed keywords

ABAGOVOMAB; ALTRETAMINE; BEVACIZUMAB; CANCER VACCINE; CARBOPLATIN; CATUMAXOMAB; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPITHELIAL CELL ADHESION MOLECULE; ETOPOSIDE; FLUDARABINE; GAMMA INTERFERON; GEMCITABINE; IFOSFAMIDE; INTERLEUKIN 15; INTERLEUKIN 2; LYMPHOCYTE ANTIGEN RECEPTOR; OREGOVOMAB; PACLITAXEL; TOPOTECAN; VASCULOTROPIN;

EID: 84890249562     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2014.859671     Document Type: Review
Times cited : (6)

References (99)
  • 1
    • 84875804295 scopus 로고    scopus 로고
    • Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
    • Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49(6):1374-403
    • (2013) Eur J Cancer , vol.49 , Issue.6 , pp. 1374-1403
    • Ferlay, J.1    Steliarova-Foucher, E.2    Lortet-Tieulent, J.3
  • 2
    • 77954340426 scopus 로고    scopus 로고
    • Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    • Colombo N, Peiretti M, Parma G, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v23-30
    • (2010) Ann Oncol , vol.21 , Issue.SUPPL. 5
    • Colombo, N.1    Peiretti, M.2    Parma, G.3
  • 4
    • 0037440317 scopus 로고    scopus 로고
    • International collaborative ovarian neoplasm trial 1: A randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer
    • Colombo N, Guthrie D, Chiari S, et al. International collaborative ovarian neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst 2003;95(2):125-32
    • (2003) J Natl Cancer Inst , vol.95 , Issue.2 , pp. 125-132
    • Colombo, N.1    Guthrie, D.2    Chiari, S.3
  • 5
    • 0037440295 scopus 로고    scopus 로고
    • Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European organisation for research and treatment of cancer-adjuvant chemotherapy in ovarian neoplasm trial
    • Trimbos JB, Vergote I, Bolis G, et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European organisation for research and treatment of cancer-adjuvant chemotherapy in ovarian neoplasm trial. J Natl Cancer Inst 2003;95(2):113-25
    • (2003) J Natl Cancer Inst , vol.95 , Issue.2 , pp. 113-125
    • Trimbos, J.B.1    Vergote, I.2    Bolis, G.3
  • 6
    • 0141688377 scopus 로고    scopus 로고
    • Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study
    • Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21(17):3194-200
    • (2003) J Clin Oncol , vol.21 , Issue.17 , pp. 3194-3200
    • Ozols, R.F.1    Bundy, B.N.2    Greer, B.E.3
  • 7
    • 9744223515 scopus 로고    scopus 로고
    • Phase III randomized trial of docetaxelcarboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma
    • Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxelcarboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004;96(22):1682-91
    • (2004) J Natl Cancer Inst , vol.96 , Issue.22 , pp. 1682-1691
    • Vasey, P.A.1    Jayson, G.C.2    Gordon, A.3
  • 8
    • 0026018186 scopus 로고
    • Responses to second-line cisplatinbased intraperitoneal therapy in ovarian cancer: Influence of a prior response to intravenous cisplatin
    • Markman M, Reichman B, Hakes T, et al. Responses to second-line cisplatinbased intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol 1991;9(10):1801-5
    • (1991) J Clin Oncol , vol.9 , Issue.10 , pp. 1801-1805
    • Markman, M.1    Reichman, B.2    Hakes, T.3
  • 9
    • 84875036495 scopus 로고    scopus 로고
    • Palliative systemic therapy for women with recurrent epithelial ovarian cancer: Current options
    • Elit L, Hirte H. Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options. Onco Targets Ther 2013;6:107-18
    • (2013) Onco Targets Ther , vol.6 , pp. 107-118
    • Elit, L.1    Hirte, H.2
  • 10
    • 0027131189 scopus 로고
    • Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes
    • Vaage J, Donovan D, Mayhew E, et al. Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes. Cancer 1993;72(12):3671-5
    • (1993) Cancer , vol.72 , Issue.12 , pp. 3671-3675
    • Vaage, J.1    Donovan, D.2    Mayhew, E.3
  • 11
    • 18144379214 scopus 로고    scopus 로고
    • Correlation of epidermal growth factor receptor expression with tumor microdensity vessels and with vascular endothelial growth factor expression in ovarian carcinoma
    • Raspollini MR, Castiglione F, Garbini F, et al. Correlation of epidermal growth factor receptor expression with tumor microdensity vessels and with vascular endothelial growth factor expression in ovarian carcinoma. Int J Surg Pathol 2005;13(2):135-42
    • (2005) Int J Surg Pathol , vol.13 , Issue.2 , pp. 135-142
    • Raspollini, M.R.1    Castiglione, F.2    Garbini, F.3
  • 12
    • 84855425106 scopus 로고    scopus 로고
    • Incorporation of bevacizumab in the primary treatment of ovarian cancer
    • Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365(26):2473-83
    • (2011) N Engl J Med , vol.365 , Issue.26 , pp. 2473-2483
    • Burger, R.A.1    Brady, M.F.2    Bookman, M.A.3
  • 13
    • 84855466019 scopus 로고    scopus 로고
    • A phase 3 trial of bevacizumab in ovarian cancer
    • Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365(26):2484-96
    • (2011) N Engl J Med , vol.365 , Issue.26 , pp. 2484-2496
    • Perren, T.J.1    Swart, A.M.2    Pfisterer, J.3
  • 14
    • 0036173892 scopus 로고    scopus 로고
    • Heterogeneity of ovarian cancer: Relationships among histological group, stage of disease, tumor markers, patient characteristics, and survival
    • Pieretti M, Hopenhayn-Rich C, Khattar NH, et al. Heterogeneity of ovarian cancer: relationships among histological group, stage of disease, tumor markers, patient characteristics, and survival. Cancer Invest 2002;20(1):11-23
    • (2002) Cancer Invest , vol.20 , Issue.1 , pp. 11-23
    • Pieretti, M.1    Hopenhayn-Rich, C.2    Khattar, N.H.3
  • 15
    • 0034332322 scopus 로고    scopus 로고
    • The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma
    • Shahin MS, Hughes JH, Sood AK, Buller RE. The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer 2000;89(9):2006-17
    • (2000) Cancer , vol.89 , Issue.9 , pp. 2006-2017
    • Shahin, M.S.1    Hughes, J.H.2    Sood, A.K.3    Buller, R.E.4
  • 16
    • 84863599600 scopus 로고    scopus 로고
    • HER2 expression in ovarian carcinoma: Caution and complexity in biomarker analysis
    • author reply 71-2
    • McCaughan H, Um I, Langdon SP, et al. HER2 expression in ovarian carcinoma: caution and complexity in biomarker analysis. J Clin Pathol 2012;65(7):670-1; author reply 71-2
    • (2012) J Clin Pathol , vol.65 , Issue.7 , pp. 670-671
    • McCaughan, H.1    Um, I.2    Langdon, S.P.3
  • 17
    • 84873844780 scopus 로고    scopus 로고
    • Staining of MUC1 in ovarian cancer tissues with PankoMab-GEX detecting the tumour-associated epitope, TAMUC1, as compared to antibodies HMFG-1 and 115D8
    • Dian D, Lenhard M, Mayr D, et al. Staining of MUC1 in ovarian cancer tissues with PankoMab-GEX detecting the tumour-associated epitope, TAMUC1, as compared to antibodies HMFG-1 and 115D8. Histol Histopathol 2013;28(2):239-44
    • (2013) Histol Histopathol , vol.28 , Issue.2 , pp. 239-244
    • Dian, D.1    Lenhard, M.2    Mayr, D.3
  • 18
    • 0028063239 scopus 로고
    • Isolation and characterization of CD47 glycoprotein: A multispanning membrane protein which is the same as integrin-associated protein (IAP) and the ovarian tumour marker OA3
    • Mawby WJ, Holmes CH, Anstee DJ, et al. Isolation and characterization of CD47 glycoprotein: a multispanning membrane protein which is the same as integrin-associated protein (IAP) and the ovarian tumour marker OA3. Biochem J 1994;304(Pt 2):525-30
    • (1994) Biochem J , vol.304 , Issue.PART 2 , pp. 525-530
    • Mawby, W.J.1    Holmes, C.H.2    Anstee, D.J.3
  • 19
    • 0032484540 scopus 로고    scopus 로고
    • Role of folate receptor and reduced folate carrier in the transport of 5- methyltetrahydrofolic acid in human ovarian carcinoma cells
    • Corona G, Giannini F, Fabris M, et al. Role of folate receptor and reduced folate carrier in the transport of 5- methyltetrahydrofolic acid in human ovarian carcinoma cells. Int J Cancer 1998;75(1):125-33
    • (1998) Int J Cancer , vol.75 , Issue.1 , pp. 125-133
    • Corona, G.1    Giannini, F.2    Fabris, M.3
  • 20
    • 34247618735 scopus 로고    scopus 로고
    • Expression of TAG-72 in ovarian cancer and its correlation with tumor stage and patient prognosis
    • Ponnusamy MP, Venkatraman G, Singh AP, et al. Expression of TAG-72 in ovarian cancer and its correlation with tumor stage and patient prognosis. Cancer Lett 2007;251(2):247-57
    • (2007) Cancer Lett , vol.251 , Issue.2 , pp. 247-257
    • Ponnusamy, M.P.1    Venkatraman, G.2    Singh, A.P.3
  • 22
    • 0348223937 scopus 로고    scopus 로고
    • Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms
    • Yakirevich E, Sabo E, Lavie O, et al. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms. Clin Cancer Res 2003;9(17):6453-60
    • (2003) Clin Cancer Res , vol.9 , Issue.17 , pp. 6453-6460
    • Yakirevich, E.1    Sabo, E.2    Lavie, O.3
  • 23
    • 0034630731 scopus 로고    scopus 로고
    • An Oacetylated sialyl-Tn is involved in ovarian cancer-associated antigenicity
    • Toba S, Tenno M, Kurosaka A. An Oacetylated sialyl-Tn is involved in ovarian cancer-associated antigenicity. Biochem Biophys Res Commun 2000;271(2):281-6
    • (2000) Biochem Biophys Res Commun , vol.271 , Issue.2 , pp. 281-286
    • Toba, S.1    Tenno, M.2    Kurosaka, A.3
  • 24
    • 77949429770 scopus 로고    scopus 로고
    • Ovarian cancer immunotherapy: Opportunities, progresses and challenges
    • Liu B, Nash J, Runowicz C, et al. Ovarian cancer immunotherapy: opportunities, progresses and challenges. J Hematol Oncol 2010;3:7
    • (2010) J Hematol Oncol , vol.3 , pp. 7
    • Liu, B.1    Nash, J.2    Runowicz, C.3
  • 26
    • 33846444354 scopus 로고    scopus 로고
    • High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer
    • Piersma SJ, Jordanova ES, van Poelgeest MI, et al. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res 2007;67(1):354-61
    • (2007) Cancer Res , vol.67 , Issue.1 , pp. 354-361
    • Piersma, S.J.1    Jordanova, E.S.2    Van Poelgeest, M.I.3
  • 27
    • 84870288924 scopus 로고    scopus 로고
    • Cancer immunoediting by the innate immune system in the absence of adaptive immunity
    • O'Sullivan T, Saddawi-Konefka R, Vermi W, et al. Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J Exp Med 2012;209(10):1869-82
    • (2012) J Exp Med , vol.209 , Issue.10 , pp. 1869-1882
    • O'sullivan, T.1    Saddawi-Konefka, R.2    Vermi, W.3
  • 28
    • 34248193253 scopus 로고    scopus 로고
    • Immune surveillance of tumors
    • Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest 2007;117(5):1137-46
    • (2007) J Clin Invest , vol.117 , Issue.5 , pp. 1137-1146
    • Swann, J.B.1    Smyth, M.J.2
  • 29
    • 38749145575 scopus 로고    scopus 로고
    • Correlation of NK T-like CD3 +CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy
    • Bamias A, Koutsoukou V, Terpos E, et al. Correlation of NK T-like CD3 +CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy. Gynecol Oncol 2008;108(2):421-7
    • (2008) Gynecol Oncol , vol.108 , Issue.2 , pp. 421-427
    • Bamias, A.1    Koutsoukou, V.2    Terpos, E.3
  • 30
    • 0033991158 scopus 로고    scopus 로고
    • Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance
    • Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000;74:181-273
    • (2000) Adv Immunol , vol.74 , pp. 181-273
    • Marincola, F.M.1    Jaffee, E.M.2    Hicklin, D.J.3    Ferrone, S.4
  • 31
    • 0037126310 scopus 로고    scopus 로고
    • Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
    • Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002;419(6908):734-8
    • (2002) Nature , vol.419 , Issue.6908 , pp. 734-738
    • Groh, V.1    Wu, J.2    Yee, C.3    Spies, T.4
  • 32
    • 0035874949 scopus 로고    scopus 로고
    • Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer
    • Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001;61(12):4766-72
    • (2001) Cancer Res , vol.61 , Issue.12 , pp. 4766-4772
    • Woo, E.Y.1    Chu, C.S.2    Goletz, T.J.3
  • 33
    • 18144392697 scopus 로고    scopus 로고
    • Tumour-infiltrating gamma/delta Tlymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma
    • Raspollini MR, Castiglione F, Rossi Degl'innocenti D, et al. Tumour-infiltrating gamma/delta Tlymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma. Ann Oncol 2005;16(4):590-6
    • (2005) Ann Oncol , vol.16 , Issue.4 , pp. 590-596
    • Raspollini, M.R.1    Castiglione, F.2    Rossi Degl'innocenti, D.3
  • 34
    • 9844256432 scopus 로고    scopus 로고
    • Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: Twenty-four-hour versus 7-day infusion
    • Edwards RP, Gooding W, Lembersky BC, et al. Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion. J Clin Oncol 1997;15(11):3399-407
    • (1997) J Clin Oncol , vol.15 , Issue.11 , pp. 3399-3407
    • Edwards, R.P.1    Gooding, W.2    Lembersky, B.C.3
  • 35
    • 71849090003 scopus 로고    scopus 로고
    • A phase II trial of intraperitoneal interleukin-2 in patients with platinumresistant or platinum-refractory ovarian cancer
    • Vlad AM, Budiu RA, Lenzner DE, et al. A phase II trial of intraperitoneal interleukin-2 in patients with platinumresistant or platinum-refractory ovarian cancer. Cancer Immunol Immunother 2010;59(2):293-301
    • (2010) Cancer Immunol Immunother , vol.59 , Issue.2 , pp. 293-301
    • Vlad, A.M.1    Budiu, R.A.2    Lenzner, D.E.3
  • 36
    • 0037388367 scopus 로고    scopus 로고
    • TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class Irestricted T cells specific for autologous tumor in late-stage ovarian cancer patients
    • Schlienger K, Chu CS, Woo EY, et al. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class Irestricted T cells specific for autologous tumor in late-stage ovarian cancer patients. Clin Cancer Res 2003;9(4):1517-27
    • (2003) Clin Cancer Res , vol.9 , Issue.4 , pp. 1517-1527
    • Schlienger, K.1    Chu, C.S.2    Woo, E.Y.3
  • 37
    • 33644854425 scopus 로고    scopus 로고
    • Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer
    • Goodell V, Salazar LG, Urban N, et al. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. J Clin Oncol 2006;24(5):762-8
    • (2006) J Clin Oncol , vol.24 , Issue.5 , pp. 762-768
    • Goodell, V.1    Salazar, L.G.2    Urban, N.3
  • 38
    • 0032793847 scopus 로고    scopus 로고
    • Clonal expansion of T cells that are specific for autologous ovarian tumor among tumorinfiltrating T cells in humans
    • Hayashi K, Yonamine K, Masuko-Hongo K, et al. Clonal expansion of T cells that are specific for autologous ovarian tumor among tumorinfiltrating T cells in humans. Gynecol Oncol 1999;74(1):86-92
    • (1999) Gynecol Oncol , vol.74 , Issue.1 , pp. 86-92
    • Hayashi, K.1    Yonamine, K.2    Masuko-Hongo, K.3
  • 39
    • 0027528759 scopus 로고
    • Restricted T cell receptor V-beta and J-beta usage in T cells from interleukin-2-cultured lymphocytes of ovarian and renal carcinomas
    • Halapi E, Yamamoto Y, Juhlin C, et al. Restricted T cell receptor V-beta and J-beta usage in T cells from interleukin-2-cultured lymphocytes of ovarian and renal carcinomas. Cancer Immunol Immunother 1993;36(3):191-7
    • (1993) Cancer Immunol Immunother , vol.36 , Issue.3 , pp. 191-197
    • Halapi, E.1    Yamamoto, Y.2    Juhlin, C.3
  • 40
    • 0029053749 scopus 로고
    • Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines
    • Fisk B, Blevins TL, Wharton JT, Ioannides CG. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 1995;181(6):2109-17
    • (1995) J Exp Med , vol.181 , Issue.6 , pp. 2109-2117
    • Fisk, B.1    Blevins, T.L.2    Wharton, J.T.3    Ioannides, C.G.4
  • 41
    • 0027787511 scopus 로고
    • Cytokine production by T-cell lines derived from tumor-infiltrating lymphocytes from patients with ovarian carcinoma: Tumor-specific immune responses and inhibition of antigenindependent cytokine production by ovarian tumor cells
    • Kooi S, Freedman RS, Rodriguez-Villanueva J, Platsoucas CD. Cytokine production by T-cell lines derived from tumor-infiltrating lymphocytes from patients with ovarian carcinoma: tumor-specific immune responses and inhibition of antigenindependent cytokine production by ovarian tumor cells. Lymphokine Cytokine Res 1993;12(6):429-37
    • (1993) Lymphokine Cytokine Res , vol.12 , Issue.6 , pp. 429-437
    • Kooi, S.1    Freedman, R.S.2    Rodriguez-Villanueva, J.3    Platsoucas, C.D.4
  • 42
    • 0031672721 scopus 로고    scopus 로고
    • Ovarian cancer-associated lymphocyte recognition of folate binding protein peptides
    • Peoples GE, Anderson BW, Fisk B, et al. Ovarian cancer-associated lymphocyte recognition of folate binding protein peptides. Ann Surg Oncol 1998;5(8):743-50
    • (1998) Ann Surg Oncol , vol.5 , Issue.8 , pp. 743-750
    • Peoples, G.E.1    Anderson, B.W.2    Fisk, B.3
  • 43
    • 0000052318 scopus 로고    scopus 로고
    • Tumor-infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC class II-restricted fashion
    • Dadmarz RD, Ordoubadi A, Mixon A, et al. Tumor-infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC class II-restricted fashion. Cancer J Sci Am 1996;2(5):263-72
    • (1996) Cancer J Sci Am , vol.2 , Issue.5 , pp. 263-272
    • Dadmarz, R.D.1    Ordoubadi, A.2    Mixon, A.3
  • 44
    • 0034734986 scopus 로고    scopus 로고
    • Induction of ovarian tumor-specific CD8 + cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells
    • Santin AD, Bellone S, Ravaggi A, et al. Induction of ovarian tumor-specific CD8 + cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells. Obstet Gynecol 2000;96(3):422-30
    • (2000) Obstet Gynecol , vol.96 , Issue.3 , pp. 422-430
    • Santin, A.D.1    Bellone, S.2    Ravaggi, A.3
  • 45
    • 0027265296 scopus 로고
    • T-cell recognition of ovarian cancer
    • Peoples GE, Schoof DD, Andrews JV, et al. T-cell recognition of ovarian cancer. Surgery 1993;114(2):227-34
    • (1993) Surgery , vol.114 , Issue.2 , pp. 227-234
    • Peoples, G.E.1    Schoof, D.D.2    Andrews, J.V.3
  • 46
    • 0037448353 scopus 로고    scopus 로고
    • Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer
    • Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348(3):203-13
    • (2003) N Engl J Med , vol.348 , Issue.3 , pp. 203-213
    • Zhang, L.1    Conejo-Garcia, J.R.2    Katsaros, D.3
  • 47
    • 67649624673 scopus 로고    scopus 로고
    • Intraepithelial T cells and tumor proliferation: Impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer
    • Adams SF, Levine DA, Cadungog MG, et al. Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer. Cancer 2009;115(13):2891-902
    • (2009) Cancer , vol.115 , Issue.13 , pp. 2891-2902
    • Adams, S.F.1    Levine, D.A.2    Cadungog, M.G.3
  • 48
    • 29444442811 scopus 로고    scopus 로고
    • Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
    • Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005;102(51):18538-43
    • (2005) Proc Natl Acad Sci U S A , vol.102 , Issue.51 , pp. 18538-18543
    • Sato, E.1    Olson, S.H.2    Ahn, J.3
  • 49
    • 58149303099 scopus 로고    scopus 로고
    • Prognostic significance of tumorinfiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer
    • Leffers N, Gooden MJ, de Jong RA, et al. Prognostic significance of tumorinfiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother 2009;58(3):449-59
    • (2009) Cancer Immunol Immunother , vol.58 , Issue.3 , pp. 449-459
    • Leffers, N.1    Gooden, M.J.2    De Jong, R.A.3
  • 50
    • 68149141666 scopus 로고    scopus 로고
    • Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors
    • Milne K, Kobel M, Kalloger SE, et al. Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS ONE 2009;4(7):e6412
    • (2009) PLoS ONE , vol.4 , Issue.7
    • Milne, K.1    Kobel, M.2    Kalloger, S.E.3
  • 51
    • 69849107597 scopus 로고    scopus 로고
    • Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments
    • Kryczek I, Banerjee M, Cheng P, et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009;114(6):1141-9
    • (2009) Blood , vol.114 , Issue.6 , pp. 1141-1149
    • Kryczek, I.1    Banerjee, M.2    Cheng, P.3
  • 52
    • 0027414895 scopus 로고
    • Natural killer cell activity and progression-free survival in ovarian cancer
    • Garzetti GG, Cignitti M, Ciavattini A, et al. Natural killer cell activity and progression-free survival in ovarian cancer. Gynecol Obstet Invest 1993;35(2):118-20
    • (1993) Gynecol Obstet Invest , vol.35 , Issue.2 , pp. 118-120
    • Garzetti, G.G.1    Cignitti, M.2    Ciavattini, A.3
  • 53
    • 33644652161 scopus 로고    scopus 로고
    • NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma
    • Dong HP, Elstrand MB, Holth A, et al. NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. Am J Clin Pathol 2006;125(3):451-8
    • (2006) Am J Clin Pathol , vol.125 , Issue.3 , pp. 451-458
    • Dong, H.P.1    Elstrand, M.B.2    Holth, A.3
  • 54
    • 33749016477 scopus 로고    scopus 로고
    • T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer
    • Knutson KL, Krco CJ, Erskine CL, et al. T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer. J Clin Oncol 2006;24(26):4254-61
    • (2006) J Clin Oncol , vol.24 , Issue.26 , pp. 4254-4261
    • Knutson, K.L.1    Krco, C.J.2    Erskine, C.L.3
  • 55
    • 74749105337 scopus 로고    scopus 로고
    • Expression and serum immunoreactivity of developmentally restricted differentiation antigens in epithelial ovarian cancer
    • Tchabo NE, Mhawech-Fauceglia P, Caballero OL, et al. Expression and serum immunoreactivity of developmentally restricted differentiation antigens in epithelial ovarian cancer. Cancer Immun 2009;9:6
    • (2009) Cancer Immun , vol.9 , pp. 6
    • Tchabo, N.E.1    Mhawech-Fauceglia, P.2    Caballero, O.L.3
  • 56
    • 65249173447 scopus 로고    scopus 로고
    • Adoptive cell therapy for the treatment of patients with metastatic melanoma
    • Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 2009;21(2):233-40
    • (2009) Curr Opin Immunol , vol.21 , Issue.2 , pp. 233-240
    • Rosenberg, S.A.1    Dudley, M.E.2
  • 58
    • 0037364804 scopus 로고    scopus 로고
    • Natural versus adaptive regulatory T cells
    • Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003;3(3):253-7
    • (2003) Nat Rev Immunol , vol.3 , Issue.3 , pp. 253-257
    • Bluestone, J.A.1    Abbas, A.K.2
  • 59
    • 33646371011 scopus 로고    scopus 로고
    • Foxp3 expressing CD4+ CD25+ and CD8+CD28- T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma
    • Meloni F, Morosini M, Solari N, et al. Foxp3 expressing CD4+ CD25+ and CD8+CD28- T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma. Hum Immunol 2006;67(1-2):1-12
    • (2006) Hum Immunol , vol.67 , Issue.1-2 , pp. 1-12
    • Meloni, F.1    Morosini, M.2    Solari, N.3
  • 60
    • 36049009999 scopus 로고    scopus 로고
    • Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: A Phase i clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes
    • Audia S, Nicolas A, Cathelin D, et al. Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes. Clin Exp Immunol 2007;150(3):523-30
    • (2007) Clin Exp Immunol , vol.150 , Issue.3 , pp. 523-530
    • Audia, S.1    Nicolas, A.2    Cathelin, D.3
  • 61
    • 24944519910 scopus 로고    scopus 로고
    • Proportion of CD4+CD25+ regulatory T cell is increased in the patients with ovarian carcinoma
    • Li X, Ye DF, Xie X, et al. Proportion of CD4+CD25+ regulatory T cell is increased in the patients with ovarian carcinoma. Cancer Invest 2005;23(5):399-403
    • (2005) Cancer Invest , vol.23 , Issue.5 , pp. 399-403
    • Li, X.1    Ye, D.F.2    Xie, X.3
  • 62
    • 4644237613 scopus 로고    scopus 로고
    • Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
    • Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10(9):942-9
    • (2004) Nat Med , vol.10 , Issue.9 , pp. 942-949
    • Curiel, T.J.1    Coukos, G.2    Zou, L.3
  • 63
    • 28544433483 scopus 로고    scopus 로고
    • The expression of the regulatory T cellspecific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer
    • Wolf D, Wolf AM, Rumpold H, et al. The expression of the regulatory T cellspecific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 2005;11(23):8326-31
    • (2005) Clin Cancer Res , vol.11 , Issue.23 , pp. 8326-8331
    • Wolf, D.1    Wolf, A.M.2    Rumpold, H.3
  • 64
    • 85026139580 scopus 로고    scopus 로고
    • Ovarian cancer cells induce peripheral mature dendritic cells to differentiate into macrophagelike cells in vitro
    • Chen F, Hou M, Ye F, et al. Ovarian cancer cells induce peripheral mature dendritic cells to differentiate into macrophagelike cells in vitro. Int J Gynecol Cancer 2009;19(9):1487-93
    • (2009) Int J Gynecol Cancer , vol.19 , Issue.9 , pp. 1487-1493
    • Chen, F.1    Hou, M.2    Ye, F.3
  • 65
    • 43249095919 scopus 로고    scopus 로고
    • Tumor angiogenesis
    • Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358(19):2039-49
    • (2008) N Engl J Med , vol.358 , Issue.19 , pp. 2039-2049
    • Kerbel, R.S.1
  • 66
    • 77953487609 scopus 로고    scopus 로고
    • Myeloid cells in the tumor microenvironment: Modulation of tumor angiogenesis and tumor inflammation
    • Schmid MC, Varner JA. Myeloid cells in the tumor microenvironment: modulation of tumor angiogenesis and tumor inflammation. J Oncol 2010;2010:201026
    • (2010) J Oncol , vol.2010 , pp. 201026
    • Schmid, M.C.1    Varner, J.A.2
  • 67
    • 77955549860 scopus 로고    scopus 로고
    • Myeloid-derived suppressor cells: More mechanisms for inhibiting antitumor immunity
    • Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother 2010;59(10):1593-600
    • (2010) Cancer Immunol Immunother , vol.59 , Issue.10 , pp. 1593-1600
    • Ostrand-Rosenberg, S.1
  • 68
    • 33847611968 scopus 로고    scopus 로고
    • Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
    • Hamanishi J, Mandai M, Iwasaki M, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 2007;104(9):3360-5
    • (2007) Proc Natl Acad Sci USA , vol.104 , Issue.9 , pp. 3360-3365
    • Hamanishi, J.1    Mandai, M.2    Iwasaki, M.3
  • 69
    • 33646367200 scopus 로고    scopus 로고
    • The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: Correlation with important high-risk prognostic factors
    • Ghebeh H, Mohammed S, Al-Omair A, et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 2006;8(3):190-8
    • (2006) Neoplasia , vol.8 , Issue.3 , pp. 190-198
    • Ghebeh, H.1    Mohammed, S.2    Al-Omair, A.3
  • 70
    • 70350247885 scopus 로고    scopus 로고
    • Tumor-expressed B7-H1 and B7- DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma
    • Karim R, Jordanova ES, Piersma SJ, et al. Tumor-expressed B7-H1 and B7- DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Clin Cancer Res 2009;15(20):6341-7
    • (2009) Clin Cancer Res , vol.15 , Issue.20 , pp. 6341-6347
    • Karim, R.1    Jordanova, E.S.2    Piersma, S.J.3
  • 71
    • 70349234325 scopus 로고    scopus 로고
    • B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders
    • Wilcox RA, Feldman AL, Wada DA, et al. B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood 2009;114(10):2149-58
    • (2009) Blood , vol.114 , Issue.10 , pp. 2149-2158
    • Wilcox, R.A.1    Feldman, A.L.2    Wada, D.A.3
  • 72
    • 54749135372 scopus 로고    scopus 로고
    • Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity
    • Huarte E, Cubillos-Ruiz JR, Nesbeth YC, et al. Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Res 2008;68(18):7684-91
    • (2008) Cancer Res , vol.68 , Issue.18 , pp. 7684-7691
    • Huarte, E.1    Cubillos-Ruiz, J.R.2    Nesbeth, Y.C.3
  • 73
    • 48749116913 scopus 로고    scopus 로고
    • Ovarian cancer cells modulate human blood neutrophils response to activation in vitro
    • Klink M, Jastrzembska K, Nowak M, et al. Ovarian cancer cells modulate human blood neutrophils response to activation in vitro. Scand J Immunol 2008;68(3):328-36
    • (2008) Scand J Immunol , vol.68 , Issue.3 , pp. 328-336
    • Klink, M.1    Jastrzembska, K.2    Nowak, M.3
  • 74
    • 77955862760 scopus 로고    scopus 로고
    • Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer
    • An X, Ding PR, Li YH, et al. Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer. Biomarkers 2010;15(6):516-22
    • (2010) Biomarkers , vol.15 , Issue.6 , pp. 516-522
    • An, X.1    Ding, P.R.2    Li, Y.H.3
  • 75
    • 54849431185 scopus 로고    scopus 로고
    • Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment
    • Cho H, Hur HW, Kim SW, et al. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother 2009;58(1):15-23
    • (2009) Cancer Immunol Immunother , vol.58 , Issue.1 , pp. 15-23
    • Cho, H.1    Hur, H.W.2    Kim, S.W.3
  • 76
    • 78149406896 scopus 로고    scopus 로고
    • Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer
    • Ding PR, An X, Zhang RX, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer. Int J Colorectal Dis 2010;25(12):1427-33
    • (2010) Int J Colorectal Dis , vol.25 , Issue.12 , pp. 1427-1433
    • Ding, P.R.1    An, X.2    Zhang, R.X.3
  • 77
    • 77953912251 scopus 로고    scopus 로고
    • Neutrophil to lymphocyte ratio for preoperative diagnosis of uterine sarcomas: A case-matched comparison
    • Kim HS, Han KH, Chung HH, et al. Neutrophil to lymphocyte ratio for preoperative diagnosis of uterine sarcomas: a case-matched comparison. Eur J Surg Oncol 2010;36(7):691-8
    • (2010) Eur J Surg Oncol , vol.36 , Issue.7 , pp. 691-698
    • Kim, H.S.1    Han, K.H.2    Chung, H.H.3
  • 78
    • 77957932514 scopus 로고    scopus 로고
    • High preoperative neutrophillymphocyte ratio predicts poor survival in patients with gastric cancer
    • Shimada H, Takiguchi N, Kainuma O, et al. High preoperative neutrophillymphocyte ratio predicts poor survival in patients with gastric cancer. Gastric Cancer 2010;13(3):170-6
    • (2010) Gastric Cancer , vol.13 , Issue.3 , pp. 170-176
    • Shimada, H.1    Takiguchi, N.2    Kainuma, O.3
  • 79
    • 84864518399 scopus 로고    scopus 로고
    • A phase i clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer
    • Kandalaft LE, Powell DJ, Coukos G. A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer. J Transl Med 2012;10:157
    • (2012) J Transl Med , vol.10 , pp. 157
    • Kandalaft, L.E.1    Powell, D.J.2    Coukos, G.3
  • 80
    • 84874625308 scopus 로고    scopus 로고
    • Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo costimulated T cells in recurrent ovarian cancer
    • Kandalaft LE, Powell DJ, Chiang CL, et al. Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo costimulated T cells in recurrent ovarian cancer. Oncoimmunology 2013;2(1):e22664
    • (2013) Oncoimmunology , vol.2 , Issue.1
    • Kandalaft, L.E.1    Powell, D.J.2    Chiang, C.L.3
  • 81
    • 73949118563 scopus 로고    scopus 로고
    • Maintenance immunotherapy in recurrent ovarian cancer: Long term follow-up of a phase II study
    • Recchia F, Di Orio F, Candeloro G, et al. Maintenance immunotherapy in recurrent ovarian cancer: long term follow-up of a phase II study. Gynecol Oncol 2010;116(2):202-7
    • (2010) Gynecol Oncol , vol.116 , Issue.2 , pp. 202-207
    • Recchia, F.1    Di Orio, F.2    Candeloro, G.3
  • 82
    • 78650400901 scopus 로고    scopus 로고
    • A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer
    • Geller MA, Cooley S, Judson PL, et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 2011;13(1):98-107
    • (2011) Cytotherapy , vol.13 , Issue.1 , pp. 98-107
    • Geller, M.A.1    Cooley, S.2    Judson, P.L.3
  • 83
    • 84862330575 scopus 로고    scopus 로고
    • Immunotherapy with IL-10- and IFN-g-producing CD4 effector cells modulate "Natural" and "Inducible" CD4 TReg cell subpopulation levels: Observations in four cases of patients with ovarian cancer
    • Dobrzanski MJ, Rewers-Felkins KA, Samad KA, et al. Immunotherapy with IL-10- and IFN-g-producing CD4 effector cells modulate "Natural" and "Inducible" CD4 TReg cell subpopulation levels: observations in four cases of patients with ovarian cancer. Cancer Immunol Immunother 2012;61(6):839-54
    • (2012) Cancer Immunol Immunother , vol.61 , Issue.6 , pp. 839-854
    • Dobrzanski, M.J.1    Rewers-Felkins, K.A.2    Samad, K.A.3
  • 84
    • 84856834217 scopus 로고    scopus 로고
    • Cytotoxic Tlymphocyte immunotherapy for ovarian cancer: A pilot study
    • Wright SE, Rewers-Felkins KA, Quinlin IS, et al. Cytotoxic Tlymphocyte immunotherapy for ovarian cancer: a pilot study. J Immunother 2012;35(2):196-204
    • (2012) J Immunother , vol.35 , Issue.2 , pp. 196-204
    • Wright, S.E.1    Rewers-Felkins, K.A.2    Quinlin, I.S.3
  • 85
    • 34447132202 scopus 로고    scopus 로고
    • Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti- CD3 antibody: A phase I/II study
    • Burges A, Wimberger P, Kumper C, et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti- CD3 antibody: a phase I/II study. Clin Cancer Res 2007;13(13):3899-905
    • (2007) Clin Cancer Res , vol.13 , Issue.13 , pp. 3899-3905
    • Burges, A.1    Wimberger, P.2    Kumper, C.3
  • 86
    • 77954676136 scopus 로고    scopus 로고
    • The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial
    • Heiss MM, Murawa P, Koralewski P, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer 2010;127(9):2209-21
    • (2010) Int J Cancer , vol.127 , Issue.9 , pp. 2209-2221
    • Heiss, M.M.1    Murawa, P.2    Koralewski, P.3
  • 87
    • 0009881031 scopus 로고
    • Speculations on idiotypes and homobodies
    • Lindenmann J. Speculations on idiotypes and homobodies. Ann Immunol (Paris) 1973;124(2):171-84
    • (1973) Ann Immunol (Paris) , vol.124 , Issue.2 , pp. 171-184
    • Lindenmann, J.1
  • 88
    • 0015956495 scopus 로고
    • Towards a network theory of the immune system
    • Jerne NK. Towards a network theory of the immune system. Ann Immunol (Paris) 1974;125C(1-2):373-89
    • (1974) Ann Immunol (Paris) , vol.125 C , Issue.1-2 , pp. 373-389
    • Jerne, N.K.1
  • 89
    • 12144287745 scopus 로고    scopus 로고
    • Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: Immunological response and survival (phase Ib/II)
    • Reinartz S, Kohler S, Schlebusch H, et al. Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II). Clin Cancer Res 2004;10(5):1580-7
    • (2004) Clin Cancer Res , vol.10 , Issue.5 , pp. 1580-1587
    • Reinartz, S.1    Kohler, S.2    Schlebusch, H.3
  • 90
    • 79951743656 scopus 로고    scopus 로고
    • Abagovomab: An antiidiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer
    • Grisham RN, Berek J, Pfisterer J, Sabbatini P. Abagovomab: an antiidiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer. Immunotherapy 2011;3(2):153-62
    • (2011) Immunotherapy , vol.3 , Issue.2 , pp. 153-162
    • Grisham, R.N.1    Berek, J.2    Pfisterer, J.3    Sabbatini, P.4
  • 91
    • 84876529191 scopus 로고    scopus 로고
    • Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: A phase III trial of the AGO OVAR, COGI, GINECO, and GEICO - The MIMOSA study
    • Sabbatini P, Harter P, Scambia G, et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO - the MIMOSA study. J Clin Oncol 2013;31(12):1554-61
    • (2013) J Clin Oncol , vol.31 , Issue.12 , pp. 1554-1561
    • Sabbatini, P.1    Harter, P.2    Scambia, G.3
  • 92
    • 58549088720 scopus 로고    scopus 로고
    • Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer
    • Berek J, Taylor P, McGuire W, et al. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol 2009;27(3):418-25
    • (2009) J Clin Oncol , vol.27 , Issue.3 , pp. 418-425
    • Berek, J.1    Taylor, P.2    McGuire, W.3
  • 93
    • 44949115169 scopus 로고    scopus 로고
    • CA125 velocity at relapse is a highly significant predictor of survival post relapse: Results of a 5-year follow-up survey to a randomized placebocontrolled study of maintenance oregovomab immunotherapy in advanced ovarian cancer
    • Berek JS, Taylor PT, Nicodemus CF. CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebocontrolled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. J Immunother 31(2):207-14
    • J Immunother , vol.31 , Issue.2 , pp. 207-214
    • Berek, J.S.1    Taylor, P.T.2    Nicodemus, C.F.3
  • 94
    • 14244250598 scopus 로고    scopus 로고
    • A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer
    • Ehlen TG, Hoskins PJ, Miller D, et al. A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. Int J Gynecol Cancer 2005;15(6):1023-34
    • (2005) Int J Gynecol Cancer , vol.15 , Issue.6 , pp. 1023-1034
    • Ehlen, T.G.1    Hoskins, P.J.2    Miller, D.3
  • 95
    • 65549085361 scopus 로고    scopus 로고
    • The Immune adjuvant properties of front-line carboplatin-paclitaxel: A randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer
    • Braly P, Nicodemus CF, Chu C, et al. The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer. J Immunother 2009;32(1):54-65
    • (2009) J Immunother , vol.32 , Issue.1 , pp. 54-65
    • Braly, P.1    Nicodemus, C.F.2    Chu, C.3
  • 96
    • 84855662184 scopus 로고    scopus 로고
    • Anti-idiotypic single chain mimicking CA125 linked with tuftsin provides protective immunity against ovarian cancer in mice
    • Yuan W, Xia G, Zhao C, et al. Anti-idiotypic single chain mimicking CA125 linked with tuftsin provides protective immunity against ovarian cancer in mice. Mol Med Rep 2012;5(2):388-94
    • (2012) Mol Med Rep , vol.5 , Issue.2 , pp. 388-394
    • Yuan, W.1    Xia, G.2    Zhao, C.3
  • 97
    • 84867098819 scopus 로고    scopus 로고
    • The role of costimulatory molecules in directing the functional differentiation of alloreactive T helper cells
    • Magee CN, Boenisch O, Najafian N. The role of costimulatory molecules in directing the functional differentiation of alloreactive T helper cells. Am J Transplant 2012;12(10):2588-600
    • (2012) Am J Transplant , vol.12 , Issue.10 , pp. 2588-2600
    • Magee, C.N.1    Boenisch, O.2    Najafian, N.3
  • 98
    • 0344341626 scopus 로고    scopus 로고
    • Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
    • Hodi FS, Mihm MC, Soiffer RJ, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 2003;100(8):4712-17
    • (2003) Proc Natl Acad Sci USA , vol.100 , Issue.8 , pp. 4712-4717
    • Hodi, F.S.1    Mihm, M.C.2    Soiffer, R.J.3
  • 99
    • 84879104519 scopus 로고    scopus 로고
    • Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors
    • Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G. Dual blockade of PD-1 and. CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 2013;73(12):3591-603
    • (2013) Cancer Res , vol.73 , Issue.12 , pp. 3591-3603
    • Duraiswamy, J.1    Kaluza, K.M.2    Freeman, G.J.3    Coukos, G.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.